Preclinical, Publications In vitro and in vivo pharmacological characterization of human PNPLA3-targeting short interfering RNA molecules for the treatment of metabolic dysfunction-associated steatohepatitis
Preclinical, Publications Non-HAP CAM-A ALG-006746 and ALG-006780 induce rapid HBsAg reductions in AAV-HBV mice and have favorable pharmacokinetic profiles
Preclinical, Publications Second generation HBV siRNAs with novel chemistries demonstrate improved profiles compared with ALG-125755 and other clinical stage siRNAs
Preclinical, Publications Class-A Cams Induce Cell Death Through HBV Core Protein Aggregation And Potentially Activate The Innate Immune Response
Preclinical, Publications Discovery of a Liver Targeted Oral PD-L1 Small Molecule Inhibitor for the Treatment of Chronic Hepatitis B and Liver Cancer
Preclinical, Publications Discovery of ALG-093989, a Highly Potent and Orally Bioavailable Small Molecule PD-L1 Inhibitor for the Treatment of Cancers
Preclinical, Publications Discovery of ALG-094103, a Liver-Targeted and Orally Bioavailable Small Molecule PD-L1 Inhibitor for the Treatment of Liver Cancer
Preclinical, Publications Small molecule PD-L1 inhibitor ALG-093702, Preclinical pharmacokinetic, pharmacodynamic and efficacy relationships of ALG-093702, a liver targeted PD-L1 small molecule inhibitor, in different in vivo models
Preclinical, Publications siRNA PD-L1 inhibitor, A potent human PD-L1 siRNA leads to significant reduction of AAV-HBV infected hepatocytes via immune activation in human PD-1/PD-L1 double knock in mice
Preclinical, Publications Hepatitis B virus model system, An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients